EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium

Paul van der Leest, Pim Rozendal, John Hinrichs, Carel J M van Noesel, Karen Zwaenepoel, Birgit Deiman, Cornelis J J Huijsmans, Ronald van Eijk, Ernst Jan M Speel, Rick J van Haastert, Marjolijn J L Ligtenberg iD, Ron H N van Schaik und 8 weitere

Clinical Chemistry · 02.05.2024 · 70 (5) · 759-767

DOI: 10.1093/clinchem/hvae014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 14.03.2024. Verfasst von Paul van der Leest und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Circulating Tumor DNA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Identification of tumor-derived variants in circulating tumor DNA (ctDNA) has potential as a sensitive and reliable surrogate for tumor tissue-based routine diagnostic testing. However, variations in pre(analytical) procedures affect the efficiency of ctDNA recovery. Here, an external quality assessment (EQA) was performed to determine the performance of ctDNA mutation detection work flows that are used in current diagnostic settings across laboratories within the Dutch COIN consortium (ctDNA on the road to implementation in The Netherlands).

Methods

Aliquots of 3 high-volume diagnostic leukapheresis (DLA) plasma samples and 3 artificial reference plasma samples with predetermined mutations were distributed among 16 Dutch laboratories. Participating laboratories were requested to perform ctDNA analysis for BRAF exon 15, EGFR exon 18–21, and KRAS exon 2–3 using their regular circulating cell-free DNA (ccfDNA) analysis work flow. Laboratories were assessed based on adherence to the study protocol, overall detection rate, and overall genotyping performance.

Results

A broad range of preanalytical conditions (e.g., plasma volume, elution volume, and extraction methods) and analytical methodologies (e.g., droplet digital PCR [ddPCR], small-panel PCR assays, and next-generation sequencing [NGS]) were used. Six laboratories (38%) had a performance score of >0.90; all other laboratories scored between 0.26 and 0.80. Although 13 laboratories (81%) reached a 100% overall detection rate, the therapeutically relevant EGFR p.(S752_I759del) (69%), EGFR p.(N771_H773dup) (50%), and KRAS p.(G12C) (48%) mutations were frequently not genotyped accurately.

Conclusions

Divergent (pre)analytical protocols could lead to discrepant clinical outcomes when using the same plasma samples. Standardization of (pre)analytical work flows can facilitate the implementation of reproducible liquid biopsy testing in the clinical routine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Circulating Tumor DNAHumansMutationNeoplasmsProto-Oncogene Proteins p21(ras)ErbB ReceptorsProto-Oncogene Proteins B-rafNetherlands

Substanzen

Circulating Tumor DNAProto-Oncogene Proteins p21(ras)KRAS protein, humanErbB ReceptorsProto-Oncogene Proteins B-rafBRAF protein, humanEGFR protein, human

Autor:innen und Institutionen

  • Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Pathology, Symbiant B.V., Alkmaar, the Netherlands.
  • Department of Pathology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, the Netherlands.
  • Department of Pathology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.
  • Clinical Laboratory, Catharina Hospital Eindhoven, Eindhoven, the Netherlands.

ORCID-Profile: Marjolijn J L Ligtenberg

Zitieren

APA

van der Leest, P., Rozendal, P., Hinrichs, J., van Noesel, C. J. M., Zwaenepoel, K., Deiman, B., Huijsmans, C. J. J., van Eijk, R., Speel, E. J. M., van Haastert, R. J., Ligtenberg, M. J. L., van Schaik, R. H. N., Jansen, M. P. H. M., Dubbink, H. J., de Leng, W. W., Leers, M. P. G., Tamminga, M., van den Broek, D., van Kempen, L. C., & Schuuring, E. (2024). External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium. Clinical Chemistry, 70(5), 759-767. https://doi.org/10.1093/clinchem/hvae014

Vancouver

van der Leest P, Rozendal P, Hinrichs J, van Noesel CJM, Zwaenepoel K, Deiman B, et al. External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium. Clinical Chemistry. 2024;70(5):759-767. doi:10.1093/clinchem/hvae014

BibTeX
@article{vanderLeest2024,
  author = {van der Leest, Paul and Rozendal, Pim and Hinrichs, John and van Noesel, Carel J M and Zwaenepoel, Karen and Deiman, Birgit and Huijsmans, Cornelis J J and van Eijk, Ronald and Speel, Ernst Jan M and van Haastert, Rick J and Ligtenberg, Marjolijn J L and van Schaik, Ron H N and Jansen, Maurice P H M and Dubbink, Hendrikus J and de Leng, Wendy W and Leers, Mathie P G and Tamminga, Menno and van den Broek, Daan and van Kempen, Léon C and Schuuring, Ed},
  title = {External Quality Assessment on Molecular Tumor Profiling with Circulating Tumor DNA-Based Methodologies Routinely Used in Clinical Pathology within the COIN Consortium},
  journal = {Clinical Chemistry},
  year = {2024},
  volume = {70},
  number = {5},
  pages = {759--767},
  doi = {10.1093/clinchem/hvae014}
}
Kostenlos starten →